11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The histamine H3 receptor: from discovery to clinical trials with pitolisant.

      British Journal of Pharmacology
      Animals, Clinical Trials as Topic, Drug Discovery, methods, Histamine Agonists, pharmacology, therapeutic use, Histamine Antagonists, Humans, Ligands, Piperidines, Receptors, Histamine H3, metabolism

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The third histamine receptor was discovered in 1983 by a traditional pharmacological approach, consisting of assessing the inhibitory effect of histamine on its own release from depolarized rat brain slices. The same in vitro test was used to design, in 1987, the first highly selective and potent H3-autoreceptor ligands, the antagonist thioperamide and the agonist (R)alphamethylhistamine which enhances and inhibits, respectively, the activity of histaminergic neurons in brain. The use of these research tools was instrumental in establishing the main functions of cerebral histaminergic neurons, namely their role in maintenance of wakefulness, attention, learning and other cognitive processes. In 1990, the cloning of the gene of the H3-receptor, a member of the superfamily of heptahelical receptors coupled to G proteins, paved the way to the demonstration of the high constitutive activity of the receptor, including its native form, and its participation in the tonic control of histamine release; it also facilitated the development of H3-receptor inverse agonist programs in many drug companies. Pitolisant (BF2.649, 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride) is the first inverse agonist to be introduced in the clinics. Its wake-promotion activity was evidenced in excessive diurnal sleepiness of patients with narcolepsy, Parkinson's disease or Obstructive Sleep Apnea/Hypopnea, in which this activity is characterized by a mean decrease of the Epworth Sleepiness Scale by about five units. The procognitive activity of this novel class of drugs may also find therapeutic applications in dementias, schizophrenia or attention deficit hyperactivity disorder. © 2011 The Author. British Journal of Pharmacology © 2011 The British Pharmacological Society.

          Related collections

          Author and article information

          Journal
          21615387
          3111674
          10.1111/j.1476-5381.2011.01286.x

          Chemistry
          Animals,Clinical Trials as Topic,Drug Discovery,methods,Histamine Agonists,pharmacology,therapeutic use,Histamine Antagonists,Humans,Ligands,Piperidines,Receptors, Histamine H3,metabolism

          Comments

          Comment on this article